Abstract | INTRODUCTION/PURPOSE: METHODS: The cryptophycins were prepared in 2% PEG300/8% cremophor/90% normal saline and delivered by jugular vein catheter on days 7, 9 and 11 post tumor implant to 13762 tumor-bearing rats. The cryptophycins prepared in the same formulation were administered by intravenous bolus injection on an alternate day schedule for five doses to human tumor xenograft bearing nude mice. RESULTS: CONCLUSIONS:
|
Authors | K Menon, E Alvarez, P Forler, V Phares, T Amsrud, C Shih, R Al-Awar, B A Teicher |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 46
Issue 2
Pg. 142-9
( 2000)
ISSN: 0344-5704 [Print] Germany |
PMID | 10972484
(Publication Type: Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Antineoplastic Agents
- Depsipeptides
- Lactams
- Lactones
- Peptides, Cyclic
- cryptophycin 292
- cryptophycin 55
- cryptophycin 52
|
Topics |
- Animals
- Antibiotics, Antineoplastic
(administration & dosage, therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma
(drug therapy, pathology)
- Depsipeptides
- Female
- Humans
- Infusions, Intravenous
- Lactams
(administration & dosage, therapeutic use)
- Lactones
(administration & dosage, therapeutic use)
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Mammary Neoplasms, Experimental
(drug therapy, pathology)
- Mice
- Mice, Nude
- Peptides, Cyclic
(administration & dosage, therapeutic use)
- Rats
- Rats, Inbred F344
- Transplantation, Heterologous
|